EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO

S Pizzamiglio, C M Ciniselli, E de Azambuja, D Agbor-Tarh, A Moreno-Aspitia, T M Suter, A Trama, M C De Santis, L De Cecco, M V Iorio, M Silvestri, G Pruneri und 2 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07299-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von S Pizzamiglio und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating MicroRNA, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The relevance of cardiotoxicity in the context of HER2-positive breast cancer is likely to increase with increasing patient treatment exposure, number of treatment lines, and prolonged survival. Circulating biomarkers to early identify patients at risk of cardiotoxicity could allow personalized treatment and follow-up measures. The aim of this study is to examine the relationship between circulating microRNAs and adverse cardiac events in HER2-positive breast cancer patients.

Methods

We based our work on plasma samples from NeoALTTO trial obtained at baseline, after 2 weeks of anti-HER2 therapy, and immediately before surgery. Eleven patients experienced either a symptomatic or asymptomatic cardiac event. Circulating microRNAs were profiled in all patients presenting a cardiac event (case) and in an equal number of matched patients free of reported cardiac events (controls) using microRNA-Ready-to-Use PCR (Human panel I + II). Sensitivity analyses were performed by increasing the number of controls to 1:2 and 1:3. Normalized microRNA expression levels were compared between cases and controls using the non-parametric Kruskal–Wallis test.

Results

Eight circulating microRNAs resulted differentially expressed after 2 weeks of anti-HER2 therapy between patients experiencing or not a cardiac event. Specifically, the expression of miR-125b-5p, miR-409-3p, miR-15a-5p, miR-423-5p, miR-148a-3p, miR-99a-5p, and miR-320b increased in plasma of cases as compared to controls, while the expression of miR-642a-5p decreases. Functional enrichment analysis revealed that all these microRNAs were involved in cardiomyocyte adrenergic signaling pathway.

Conclusion

This study provides proof of concept that circulating microRNAs tested soon after treatment start could serve as biomarkers of cardiotoxicity in a very early stage in breast cancer patients receiving anti-HER2 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCirculating MicroRNAErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleMiddle AgedCardiotoxicityAgedTrastuzumabAdultGene Expression Regulation, NeoplasticAntineoplastic Combined Chemotherapy ProtocolsCase-Control Studies

Stichwörter der Autor:innen

Breast cancerCardiotoxicityCirculating microRNAHER2miRNAs

Substanzen

Circulating MicroRNAErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Department of Medical Oncology, Institut Jules Bordet and L'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.
  • Frontier Science, Scotland Ltd, Kingussie, UK.
  • Mayo Clinic, Jacksonville, FL, USA.
  • Swiss Cardiovascular Center, University Hospital Bern, Inselspital, Bern, Switzerland.
  • Unit of Evaluative Epidemiology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Förderung

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Zitieren

APA

Pizzamiglio, S., Ciniselli, C. M., de Azambuja, E., Agbor-Tarh, D., Moreno-Aspitia, A., Suter, T. M., Trama, A., De Santis, M. C., De Cecco, L., Iorio, M. V., Silvestri, M., Pruneri, G., Verderio, P., & Di Cosimo, S. (2024). Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07299-6

Vancouver

Pizzamiglio S, Ciniselli CM, de Azambuja E, Agbor-Tarh D, Moreno-Aspitia A, Suter TM, et al. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07299-6

BibTeX
@article{Pizzamiglio2024,
  author = {Pizzamiglio, S and Ciniselli, C M and de Azambuja, E and Agbor-Tarh, D and Moreno-Aspitia, A and Suter, T M and Trama, A and De Santis, M C and De Cecco, L and Iorio, M V and Silvestri, M and Pruneri, G and Verderio, P and Di Cosimo, S},
  title = {Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07299-6}
}
Kostenlos starten →